The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
27630277
DOI
10.21873/anticanres.10985
PII: 36/9/4421
Knihovny.cz E-zdroje
- Klíčová slova
- Colorectal cancer, cetuximab, immune response, immunomodulation, review, targeted therapy,
- MeSH
- cetuximab terapeutické užití MeSH
- erbB receptory imunologie MeSH
- imunitní systém MeSH
- imunoterapie metody MeSH
- karcinom farmakoterapie imunologie MeSH
- kolorektální nádory farmakoterapie imunologie MeSH
- lidé MeSH
- monoklonální protilátky terapeutické užití MeSH
- panitumumab MeSH
- protinádorové látky terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- cetuximab MeSH
- EGFR protein, human MeSH Prohlížeč
- erbB receptory MeSH
- monoklonální protilátky MeSH
- panitumumab MeSH
- protinádorové látky MeSH
Monoclonal antibodies binding the epidermal growth factor receptor (EGFR), such as cetuximab or panitumumab, are widely used targeted therapeutics for the treatment of patients with colorectal cancer. The clinical significance of these drugs has so far been associated with combined chemotherapy or radiation. It has been shown that these treatment strategies have their clinical limitations and do not fully exploit the immunomodulatory effect of these drugs. In this review, we discuss the mechanisms of immunomodulation together with the anticancer immune response to the monoclonal antibodies targeted to the EGFR. The combination of anti-EGFR monoclonal antibodies with other immunotherapeutic treatment modalities certainly brings new opportunities for targeted therapy in patients with colorectal cancer.
Biomedical Center Faculty of Medicine Plzen Charles University Prague Pilsen Czech Republic
Department of Clinical Oncology Na Homolce Hospital Prague Czech Republic
Citace poskytuje Crossref.org
